




NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 10th February, 2018

To,

The Manager
Listing Department
The Bombay Stock Exchange Ltd,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524414

Sub: Submission of Standalone Unaudited Financial Results in Compliance with Regulation 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

1. Standalone Unaudited Financial Results of the Company for the quarter and Nine months ended 31st December, 2017.
2. Limited Review Report by Statutory Auditors on Unaudited Financial Results for the quarter and Nine months ended 31st December, 2017.

Thanking you,

Yours faithfully,
For **NORRIS MEDICIENS LIMITED**


Vinay Rana
(Company Secretary)





NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
 ANKLESHWAR 393 002. (Gujarat)
 Regd. Office : Plot No. 801/P, GIDC Estate,
 ANKLESHWAR 393 002. (Gujarat)
 Telephone : (02646) 223462, 227530
 Fax : (02646) 250126
 E-mail : contact@norrispharma.com
 Website : www.norrispharma.com
 CIN : L24230GJ1990PLC086581

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2017

Sr. No.	Particulars	(Rs. In Lacs)					
		Quarter Ended			Nine Months Ended		Previous Year Ended
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operation						
	Revenue from Operations	367.51	323.63	526.58	1041.39	1609.08	2045.68
	Other Income	2.71	0.82	1.21	4.11	1.58	13.96
	Total Income	370.22	324.45	527.79	1045.50	1610.66	2059.64
2	Expenses						
	(a) Cost of materials consumed	194.47	183.21	262.32	500.62	803.43	1052.05
	(b) Change in inventories of finished goods work in progress and stock-in-trade	1.74	19.04	-36.74	67.01	6.49	-11.97
	(c) Employee benefits expense	121.23	119.26	145.04	378.61	401.27	530.78
	(d) Finance cost	19.27	19.33	14.16	55.94	39.04	60.12
	(e) Depreciation and amortisation expense	16.15	16.15	14.50	48.45	43.50	64.60
	(f) Other Expense	68.38	85.01	124.59	256.25	339.46	482.36
	Total Expenses	421.24	442.00	523.87	1306.88	1633.19	2177.94
3	Profit / (Loss) before Tax	-51.02	-117.55	3.92	-261.38	-22.53	-118.30
4	Tax Expense						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) after tax for the period	-51.02	-117.55	3.92	-261.38	-22.53	-118.30
6	Other Comprehensive Income						
	(a) (i) Item that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to item that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) Item that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to item that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
7	Total Comprehensive Income for the period	-51.02	-117.55	3.92	-261.38	-22.53	-118.30
	Basic and Diluted Earning per equity share	-0.51	-1.18	0.04	-2.61	-0.23	-0.77

Notes:

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 10.02.2018.
- The Company is having one segment only and therefore Segmental Reporting is not applicable.
- The above Results, have been prepared in accordance with Ind AS as prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (LODR) Regulation, 2015 and SEBI Circular dated 05.07.2016

Reconciliation of Net Profit between Previous GAAP and Ind AS:

Standalone Financial Results.

Nature of Adjustment	Rs. In Lacs	
	Quarter Ended 31.12.2016	Nine Months Ended 31.12.2016
Net Profit Under Previous GAAP	3.92	-22.53
Actuarial gain / (Loss) on employees defined benefit funds recognised in Other Comprehensive Income (Net)	-	-
Net gain / (Loss) on financial assets at fair value through profit and Loss	-	-
Net Profit under per Ind As	3.92	-22.53

- There are no exceptional / extraordinary items during the quarter ended 31.12.2017

For NORRIS MEDICINES LIMITED

Date : 10.02.2018
 Place : Ankleshwar



Vimal D Shah
 Managing Director



C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

Date : 10th February, 2018

To
The Board of Directors
Norris Medicines Limited
Ankleshwar



Limited Review Report on Standalone Quarterly Financial Results of Norris Medicines Limited to the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015

1. INTRODUCTION

We have reviewed the accompanying statement of Standalone unaudited financial results of **NORRIS MEDICINES LIMITED** ("the company") for the Quarter and Nine Months ended **31st December, 2017**, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, which has been initiated by us for the purpose of identification. This Statement is the responsibility of the Company's Management and has been reviewed by the Audit Committee, in their meeting held on January 22, 2018 and approved by the Board of Directors, in their meeting held on January 24, 2018. Our responsibility is to issue a report on the Statement based on our review.

2. SCOPE OF REVIEW

We conducted our review in accordance with the Standard on Review Engagement (**SRE**) 2410, **Review of Interim Financial Information Performed by the Independent Auditor of the Entity** issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement of financial results is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

3. SCOPE OF REVIEW


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards, i.e. Indian Accounting Standard ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices generally in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bharuch
Date: 10/02/2018

C-24, Ground Floor,
Sardar Patel Municipal Market,
Shaktinath, Bharuch- 392001
Gujarat



For, H. N. JADAV & Co.
Chartered Accountants


CA HARISHCHANDRA N. JADAV
Proprietor
M. No. 040525
(Firm Reg. No. 103801W)